{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:19:25Z","timestamp":1792790365573,"version":"4.5.0"},"posted":{"date-parts":[[2026,9,22]]},"group-title":"Bioengineering","reference-count":34,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute","award":["R01CA240339"],"award-info":[{"award-number":["R01CA240339"]}]},{"name":"National Cancer Institute","award":["1OT2CA297288-01"],"award-info":[{"award-number":["1OT2CA297288-01"]}]},{"name":"National Cancer Institute","award":["R01CA303051"],"award-info":[{"award-number":["R01CA303051"]}]},{"name":"National Cancer Institute","award":["U01CA274276"],"award-info":[{"award-number":["U01CA274276"]}]},{"name":"National Cancer Institute","award":["K99CA293136"],"award-info":[{"award-number":["K99CA293136"]}]},{"name":"National Institute of Allergy and Infectious Diseases","award":["R0AI160052"],"award-info":[{"award-number":["R0AI160052"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Allergy and Infectious Diseases","award":["R01AI158488"],"award-info":[{"award-number":["R01AI158488"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institute of Allergy and Infectious Diseases","award":["R01AI169188"],"award-info":[{"award-number":["R01AI169188"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cancer Research UK","award":["CGCATF-2023\/100008"],"award-info":[{"award-number":["CGCATF-2023\/100008"]}],"id":[{"id":"https:\/\/ror.org\/054225q67","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Cytokines can elicit potent antitumor immunity, but their clinical use is often limited by systemic immune activation and dose-limiting toxicity. Protease-responsive masking offers a way to improve selectivity by linking cytokine activity to disease-associated protease cleavage, but current approaches have faced several challenges. Here we describe a de novo protein design strategy for generating protease-activatable cytokine prodrugs that overcomes these challenges. We use this strategy to design and characterize cytokine prodrugs and well-behaved AND-gated split systems that require both target-dependent colocalization and proteolytic unmasking to generate active cytokines. In challenging syngeneic tumor models, our IL-21 prodrugs reduced treatment-associated toxicity while maintaining antitumor efficacy.<\/jats:p>","DOI":"10.64898\/2026.09.19.752834","type":"posted-content","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:05:14Z","timestamp":1790352314000},"source":"Crossref","is-referenced-by-count":1,"title":["De novo design of protease-activatable cytokine prodrugs"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-0955","authenticated-orcid":false,"given":"Hojeong","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Biochemistry, University of Washington, Seattle, WA, USA"},{"name":"Institute for Protein Design, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julissa G.","family":"Tello","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7256-0205","authenticated-orcid":false,"given":"Chan Johng","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Washington, Seattle, WA, USA"},{"name":"Institute for Protein Design, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ho","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Washington, Seattle, WA, USA"},{"name":"Institute for Protein Design, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Peprah","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan D.","family":"Parent","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavus","family":"Atajanova","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robiah Arefin Ibn","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qiang","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Immunology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Aguirre","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Dougan","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Immunology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"},{"name":"Department of Medicine, Harvard Medical School, Boston, MA, USA"},{"name":"Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Washington, Seattle, WA, USA"},{"name":"Institute for Protein Design, University of Washington, Seattle, WA, USA"},{"name":"Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026093020500424000_2026.09.19.752834v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0328-y"},{"key":"2026093020500424000_2026.09.19.752834v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9"},{"key":"2026093020500424000_2026.09.19.752834v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.11.011"},{"key":"2026093020500424000_2026.09.19.752834v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114112"},{"key":"2026093020500424000_2026.09.19.752834v1.5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","year":"2024","journal-title":"Signal Transduct. Target. Ther"},{"key":"2026093020500424000_2026.09.19.752834v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0830-7"},{"key":"2026093020500424000_2026.09.19.752834v1.7","doi-asserted-by":"crossref","first-page":"eadx1582","DOI":"10.1126\/sciimmunol.adx1582","article-title":"Design of a potent interleukin-21 mimic for cancer immunotherapy","volume":"10","year":"2025","journal-title":"Sci. Immunol"},{"key":"2026093020500424000_2026.09.19.752834v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.03.006"},{"key":"2026093020500424000_2026.09.19.752834v1.9","doi-asserted-by":"crossref","first-page":"e153604","DOI":"10.1172\/JCI153604","article-title":"Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity","volume":"132","year":"2022","journal-title":"J. Clin. Invest"},{"key":"2026093020500424000_2026.09.19.752834v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01510-z"},{"key":"2026093020500424000_2026.09.19.752834v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22980-w"},{"key":"2026093020500424000_2026.09.19.752834v1.12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","article-title":"Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker","volume":"6","year":"2022","journal-title":"Nat. Biomed. Eng"},{"key":"2026093020500424000_2026.09.19.752834v1.13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6899"},{"key":"2026093020500424000_2026.09.19.752834v1.14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-cancerbio-030617-050549","article-title":"Harnessing protease activity to improve cancer care","volume":"2","year":"2018","journal-title":"Annu. Rev. Cancer Biol"},{"key":"2026093020500424000_2026.09.19.752834v1.15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1515\/hsz-2018-0451","article-title":"The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation","volume":"400","year":"2019","journal-title":"Biol. Chem"},{"key":"2026093020500424000_2026.09.19.752834v1.16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41592-025-02975-x","article-title":"Atom-level enzyme active site scaffolding using RFdiffusion2","volume":"23","year":"2026","journal-title":"Nat. Methods"},{"key":"2026093020500424000_2026.09.19.752834v1.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.add2187"},{"key":"2026093020500424000_2026.09.19.752834v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38328-5"},{"key":"2026093020500424000_2026.09.19.752834v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.015"},{"key":"2026093020500424000_2026.09.19.752834v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2010.12.002"},{"key":"2026093020500424000_2026.09.19.752834v1.21","doi-asserted-by":"publisher","DOI":"10.1186\/1479-7364-4-3-194"},{"key":"2026093020500424000_2026.09.19.752834v1.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0495"},{"key":"2026093020500424000_2026.09.19.752834v1.23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002447"},{"key":"2026093020500424000_2026.09.19.752834v1.24","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: An open-label phase I\/II trial","volume":"28","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"2026093020500424000_2026.09.19.752834v1.25","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.2020.38.15_suppl.3058","article-title":"Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results","volume":"38","year":"2020","journal-title":"J. Clin. Oncol"},{"key":"2026093020500424000_2026.09.19.752834v1.26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006682"},{"key":"2026093020500424000_2026.09.19.752834v1.27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/1535-7163.MCT-23-0336","article-title":"XTX301, a tumor-activated interleukin-12 has the potential to widen the therapeutic index of IL12 treatment for solid tumors as evidenced by preclinical studies","volume":"23","year":"2024","journal-title":"Mol. Cancer Ther"},{"key":"2026093020500424000_2026.09.19.752834v1.28","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1200\/JCO.2024.42.16_suppl.2623","article-title":"A phase 1\/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab","volume":"42","year":"2024","journal-title":"J. Clin. Oncol"},{"key":"2026093020500424000_2026.09.19.752834v1.29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/2326-6066.CIR-21-0831","article-title":"Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression","volume":"10","year":"2022","journal-title":"Cancer Immunol. Res"},{"key":"2026093020500424000_2026.09.19.752834v1.30","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A Probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity","volume":"82","year":"2022","journal-title":"Cancer Res"},{"key":"2026093020500424000_2026.09.19.752834v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5"},{"key":"2026093020500424000_2026.09.19.752834v1.32","doi-asserted-by":"crossref","first-page":"190235","DOI":"10.1098\/rsob.190235","article-title":"Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH","volume":"10","year":"2020","journal-title":"Open Biol"},{"key":"2026093020500424000_2026.09.19.752834v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2005.12.023"},{"key":"2026093020500424000_2026.09.19.752834v1.34","doi-asserted-by":"publisher","DOI":"10.1038\/90273"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.19.752834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:50:17Z","timestamp":1790826617000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.19.752834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":34,"URL":"https:\/\/doi.org\/10.64898\/2026.09.19.752834","relation":{},"subject":[],"published":{"date-parts":[[2026,9,22]]},"subtype":"preprint"}}